Day One Biopharmaceuticals, Inc. (DAWN)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Total revenues | 33,908 | 30,761 | 93,761 | |
| Cost of product revenue | - | 2,884 | 1,590 | |
| Research and development | 36,149 | 39,619 | 33,563 | |
| Selling, general and administrative | 28,968 | 29,325 | 28,972 | |
| Cost of product and license revenue | 3,765 | - | - | |
| Total cost and operating expenses | 68,882 | 71,828 | 64,125 | |
| Loss from operations | -34,974 | -41,067 | 29,636 | |
| Other expense, net | -19 | -23 | 1,197 | |
| Investment income, net | 4,671 | 5,094 | 5,322 | |
| Gain from sale of priority review voucher | - | - | - | |
| Total non-operating income, net | 4,652 | 5,071 | 6,519 | |
| Loss before income taxes | 30,322 | 35,996 | -36,155 | |
| Income tax expense | - | - | -882 | |
| Net loss | -30,322 | -35,996 | 37,037 | |
| Earnings per share, basic | -0.29 | -0.35 | 0.38 | |
| Earnings per share, diluted | -0.29 | -0.35 | 0.38 | |
| Weighted average number of shares outstanding, basic | 103,069,154 | 102,710,382 | 96,623,123 | |
| Weighted average number of shares outstanding, diluted | 103,069,154 | 102,710,382 | 96,937,759 | |